Fegan C D
Department of Haematology, Birmingham Heartlands Hospital.
Hosp Med. 1998 Feb;59(2):145-8.
Tinzaparin is a low molecular weight heparin which is given subcutaneously once daily without the need for laboratory monitoring. Already established as effective therapy for deep venous thrombosis, in November 1997 it became the first low molecular weight heparin to be licensed for the treatment of pulmonary embolism.
亭扎肝素是一种低分子量肝素,每天皮下注射一次,无需实验室监测。它已被确立为治疗深静脉血栓形成的有效疗法,1997年11月,它成为首个被批准用于治疗肺栓塞的低分子量肝素。